Create account

Coverage dated October 14, 2026 to October 15, 2026

Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks

Headline from MedicalXpress

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes …

MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    GLP-1 Drugs Cut Schizophrenia Hospital Visits, Study Finds (opens Bloomberg)

    Published

    Bloomberg's feed description

    People with schizophrenia who were also taking GLP-1 drugs for diabetes had fewer psychiatric relapses in a large study of US health records, indicating another potential benefit from the medicines.

  2. Quartz

    Weight loss drugs linked to fewer psychiatric admissions in schizophrenia and diabetes (opens Quartz)

    Published

    Quartz's feed description

    A Lancet Psychiatry study of more than 70,000 U.S. adults is observational and cannot show the drugs cause the lower risk

  3. MedicalXpress

    Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks (opens MedicalXpress)

    Published

    MedicalXpress's feed description

    Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes …

Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks | Since Then